StoneX Group’s Cognition Therapeutics CGTX Stock Holding History

StoneX Group’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,000	Closed	-$13.5K	–	970
2025 Q4	$13.5K	Buy	+10,000	New	+$16.2K	﹤0.01%	989

Other funds holding CGTX

BCM

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HCM

Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

StoneX Group's CGTX Position: Q1 2026 in Review

StoneX Group sold out of Cognition Therapeutics (CGTX) in Q1 2026, closing a stake of 10,000 shares — an estimated $13.5K sold.

StoneX Group first reported a position in CGTX in Q4 2025 and held it in 1 quarter. The position peaked at $13.5K in Q4 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

StoneX Group reported no remaining Cognition Therapeutics position as of Q1 2026 after selling out during the quarter.
StoneX Group sold 10,000 Cognition Therapeutics shares in Q1 2026, an estimated $13.5K.
StoneX Group first reported a position in Cognition Therapeutics in Q4 2025 and held it in 1 quarter.
StoneX Group's Cognition Therapeutics position peaked at $13.5K in Q4 2025.
75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on StoneX Group's 13F filing for Q1 2026, filed 14 May 2026.